Item no. |
LEIN-C1614-1.0mg |
Manufacturer |
Leinco Technologies
|
Amount |
1 mg |
Quantity options |
1 mg
100 mg
25 mg
5 mg
50 mg
|
Category |
|
Type |
Antibody Monoclonal |
Applications |
WB, other, IV |
Clone |
9H10 |
Specific against |
Mouse (Murine, Mus musculus) |
Host |
Hamster - Syrian |
Purity |
> 95% by SDS-PAGE and ≥ 95% monomer by analytical SEC |
Citations |
1.) Wurster S. et al. (2020) The Journal of Infectious Diseases 222(6):1989–994 |
NCBI |
12477 |
ECLASS 10.1 |
42030590 |
ECLASS 11.0 |
42030590 |
UNSPSC |
12352203 |
Shipping condition |
Cool pack |
Available |
|
Manufacturer - Category |
Purified in vivo Functional Grade>Gold Purified Bulk Antibodies|Primary Monoclonal Antibodies>Growth Factors and Cytokines|Primary Monoclonal Antibodies>Immune Checkpoints|Monoclonal Antibodies|Purified in vivo Functional Grade|Primary Monoclonal Antibodies>Surfacetag Mouse CD Markers |
Manufacturer - Targets |
CTLA-4 |
Country of Origin |
USA |
Shipping Temperature |
Next Day 2-8°C |
Storage Conditions |
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
Product Description |
CTLA-4 is a 33 kD member of the Ig superfamily similar to CD28 in amino acid sequence, structure, and genomic organization. CTLA-4 is a protein receptor that functions as an immune checkpoint and downregulates immune responses. It is involved in the development of protective immunity and thymocyte regulation, in addition to the induction and maintenance of immunological tolerance. CTLA-4 has therapeutic potential both as an agonist to reduce immune activity, and an antagonist to increase immune activity. |
Background |
CTLA-4 is a 33 kD member of the Ig superfamily similar to CD28 in amino acid sequence, structure, and genomic organization. CTLA-4 is a protein receptor that functions as an immune checkpoint and downregulates immune responses. It is involved in the development of protective immunity and thymocyte regulation, in addition to the induction and maintenance of immunological tolerance. CTLA-4 has therapeutic potential both as an agonist to reduce immune activity, and an antagonist to increase immune activity. |
Function |
Negative regulator of T cell activation |
PubMed |
CTLA-4 |
Ligand/Receptor |
CD80 (B7-1), CD86 (B7-2) |
Manufacturer - Specificity |
Clone 9H10 recognizes an epitope on mouse CTLA-4. |
RRID |
AB_2737453 |
Concentration |
≥ 5.0 mg/ml |
Formulation |
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
Product Preparation |
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
Antigen Distribution |
CTLA-4 is expressed on activated T and B lymphocytes. |
Endotoxin Level |
≤ 1.0 EU/mg |
Immunogen |
Mouse CTLA-4-human IgG1 fusion protein |
Additonal Information |
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.